Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally advanced esophageal cancer. A total of 44 patients with resectable esophageal squamous cell carcinoma (ESCC) will be enrolled.All enrolled subjects will receive induction therapy with the combination of a CTLA-4 inhibitor and a PD-1 inhibitor. Three weeks afterwards, patients will transition to concurrent chemoradiotherapy combined with PD-1 inhibitor. Intensity-modulated radiotherapy (IMRT) will be delivered at a total dose of 40 Gy in 20 fractions. Radical esophagectomy with two-field thoracic and abdominal lymph node dissection will be performed 6-8 weeks after completion of chemoradiotherapy.The primary objective of this trial is to evaluate the efficacy and safety of the triplet regimen consisting of CTLA-4 inhibitor plus PD-1 inhibitor combined with preoperative chemoradiotherapy in locally advanced esophageal cancer, so as to further optimize the multimodal therapeutic strategy for esophageal cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak przełyku (typ płaskonabłonkowy) możliwy do usunięcia chirurgicznie
- •Pacjent nigdy wcześniej nie leczony na raka
- •Wiek 18-75 lat
- •Oczekiwana długość życia powyżej 6 miesięcy
- •Sprawne funkcjonowanie nerek, wątroby i krwiotwórczych zgodnie z normami laboratoryjnymi
- •Dobra ogólna kondycja fizyczna (ECOG 0-1)
- •Możliwość zrozumienia badania i podpisania zgody
- •Chęć stosowania antykoncepcji (kobiety i mężczyźni w wieku rozrodczym)
✗ Disqualifies
- •Wcześniejsze leczenie raka (chemioterapia, radioterapia, operacja lub immunoterapia)
- •Alergia na którykolwiek z leków badania
- •Zaburzenia krwawienia
- •Ciąża lub karmienie piersią
- •Nieusuwalna choroba z powodu innych niekontrolowanych stanów
- •Brak zdolności do wyrażenia świadomej zgody
- •Neuropatia obwodowa (uszkodzenie nerwów)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
No.651 Dongfeng East Road,Guangzhou
Guangzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.